Late Thursday, Black Diamond Therapeutics Pricing Its Underwritten Public Offering Of 15M Shares At $5/Share, For Gross Proceeds Of $75M
Portfolio Pulse from Benzinga Newsdesk
Black Diamond Therapeutics has priced its underwritten public offering of 15 million shares at $5 per share, aiming to raise gross proceeds of $75 million.
June 30, 2023 | 8:21 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Black Diamond Therapeutics' public offering of 15 million shares at $5 per share could impact its stock price in the short term.
Public offerings often lead to a dilution of shares, which can result in a decrease in the stock price. Given the size of the offering, it's likely to have a significant impact on BDTX's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100